Drug & intervention
afatinib dimaleate
RxCUI 1430441
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
5 shownTo Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 FusionNCT04814056 · 2021-06-01
UNKNOWNPembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to ErlotinibNCT02364609 · 2015-09-30
COMPLETEDTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITINGS1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerNCT02438722 · 2015-05-07
COMPLETEDLong-term Observation PMS for AfatinibNCT02131259 · 2014-05-07
COMPLETEDConditions being studied
Recurrent Non-Small Cell Lung Carcinoma2Stage IV Non-Small Cell Lung Cancer2Advanced Lymphoma1Advanced Malignant Solid Neoplasm1Bladder Carcinoma1Breast Carcinoma1Carcinoma, Non-Small-Cell Lung1Cervical Carcinoma1Colon Carcinoma1Colorectal Carcinoma1Endometrial Carcinoma1Esophageal Carcinoma1Exocrine Pancreas Carcinoma1Gastric Carcinoma1Glioma1Head and Neck Carcinoma1Hematopoietic and Lymphoid Cell Neoplasm1Kidney Carcinoma1Liver Carcinoma1Lung Carcinoma1
Research locations
SacramentoCalifornia, United States3AlbuquerqueNew Mexico, United States2AllentownPennsylvania, United States2AnaheimCalifornia, United States2Ann ArborMichigan, United States2AshevilleNorth Carolina, United States2BakersfieldCalifornia, United States2BillingsMontana, United States2BoiseIdaho, United States2CantonOhio, United States2ChattanoogaTennessee, United States2CincinnatiOhio, United States2
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.